Intermedix, Inc. – Trademark Portfolio
Entity Type: 03
Intermedix, Inc. holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 35 (Advertising & Business) — 1 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 4 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include TRIPTIX. The owner is based in Houston, TX.
Suite 805
Houston, TX 77084
Showing of trademarks Trademarks
Trademark Classifications
Intermedix, Inc.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Advertising; business management; business administration; office functions
Scientific and technological services; industrial analysis and research services
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does Intermedix, Inc. have?
Intermedix, Inc. has 2 U.S. trademarks filed with the USPTO. Of these, 1 registered, 1 cancelled.
What trademark classes does Intermedix, Inc. file in?
Intermedix, Inc. files trademarks across 4 Nice Classification classes. The most active classes are Class 35 (Advertising & Business), Class 42 (Computer & Scientific), Class 9 (Computers & Electronics), Class 44 (Medical Services). Class 35 covers advertising; business management; business administration; office functions.
What are Intermedix, Inc.'s most well-known trademarks?
Intermedix, Inc.'s registered trademark portfolio includes well-known marks such as TRIPTIX. These are among 1 currently registered trademark in the portfolio.
What is Intermedix, Inc.'s trademark registration success rate?
Intermedix, Inc. has a 50% trademark registration rate, with 1 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.